AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
+1.45%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$4.3B
AUM Growth
+$4.3B
(+12%)
Cap. Flow
+$486M
Cap. Flow
% of AUM
11.31%
Top 10 Holdings %
Top 10 Hldgs %
29.76%
Holding
319
New
63
Increased
77
Reduced
60
Closed
90
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$97M |
| 2 |
Exact Sciences
EXAS
|
$90.9M |
| 3 |
Icon
ICLR
|
$87.7M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$71.6M |
| 5 |
GSK
GSK
|
$62.7M |
Top Sells
| 1 |
Alkermes
ALKS
|
$40.5M |
| 2 |
PTC Therapeutics
PTCT
|
$38.7M |
| 3 |
Shake Shack
SHAK
|
$34.8M |
| 4 |
Incyte
INCY
|
$29.6M |
| 5 |
Cytokinetics
CYTK
|
$27.5M |
Sector Composition
| 1 | Healthcare | 67.09% |
| 2 | Consumer Discretionary | 10.89% |
| 3 | Consumer Staples | 9.15% |
| 4 | Technology | 8.92% |
| 5 | Communication Services | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$3.92B
| $288M | 3.93% | 6,378,000 -856,898 | -12% | -$38.7M |
|
2
Supernus Pharmaceuticals
SUPN
$2.53B
| $175M | 2.39% | 4,836,000 -260,000 | -5% | -$9.4M |
|
3
Travere Therapeutics
TVTX
$1.56B
| $128M | 1.75% | 7,358,000 -290,000 | -4% | -$5.05M |
|
|
4
Incyte
INCY
$16.5B
| $122M | 1.67% | 1,767,830 -428,275 | -20% | -$29.6M |
|
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $122M | 1.66% | 892,000 +710,619 | +392% | +$97M |
|
6
Immunovant
IMVT
$2.56B
| $95.9M | 1.31% | 3,870,586 +322,586 | +9% | +$7.99M |
|
|
7
Exact Sciences
EXAS
$8.98B
| $90.9M | 1.24% | +1,617,000 | New | +$90.9M |
|
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $90.2M | 1.23% | 224,016 +177,887 | +386% | +$71.6M |
|
|
9
Icon
ICLR
$13.8B
| $87.7M | 1.2% | +418,112 | New | +$87.7M |
|
|
10
GSK
GSK
$79.9B
| $80.4M | 1.1% | 2,378,000 +1,854,000 | +354% | +$62.7M |
|
11
FIVE9
FIVN
$2.08B
| $80.1M | 1.09% | 1,970,207 +94,207 | +5% | +$3.83M |
|
|
NARI
12
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $79.9M | 1.09% | 1,565,577 -256,423 | -14% | -$13.1M |
|
13
Humana
HUM
$36.5B
| $79.2M | 1.08% | 312,000 +133,915 | +75% | +$34M |
|
14
argenx
ARGX
$43.6B
| $76.3M | 1.04% | 124,000 -28,000 | -18% | -$17.2M |
|
15
Grifois
GRFS
$6.78B
| $74.7M | 1.02% | 10,036,000 +500,000 | +5% | +$3.72M |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $74.4M | 1.02% | 2,264,304 +57,234 | +3% | +$1.88M |
|
17
AB InBev
BUD
$122B
| $68M | 0.93% | 1,359,000 +267,000 | +24% | +$13.4M |
|
18
Dentsply Sirona
XRAY
$2.85B
| $66.4M | 0.91% | 3,499,628 +852,856 | +32% | +$16.2M |
|
19
PENN Entertainment
PENN
$2.95B
| $65.4M | 0.89% | 3,298,268 +903,958 | +38% | +$17.9M |
|
20
Biohaven
BHVN
$1.63B
| $62.5M | 0.85% | 1,672,298 +472,803 | +39% | +$17.7M |
|
|
21
Cytokinetics
CYTK
$4.23B
| $61.7M | 0.84% | 1,312,000 -584,575 | -31% | -$27.5M |
|
22
Novo Nordisk
NVO
$251B
| $61.2M | 0.84% | 712,000 +147,000 | +26% | +$12.6M |
|
23
Sanofi
SNY
$121B
| $60.2M | 0.82% | 1,248,000 +668,000 | +115% | +$32.2M |
|
24
Medtronic
MDT
$119B
| $59.9M | 0.82% | 750,164 +114,236 | +18% | +$9.13M |
|
25
Aurinia Pharmaceuticals
AUPH
$1.58B
| $57.5M | 0.78% | 6,400,000 -1,800,000 | -22% | -$16.2M |
|